BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
UBS
US Army
Teva
Dow
Harvard Business School
Accenture
McKesson
Merck
Colorcon

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022225

« Back to Dashboard

NDA 022225 describes BRIDION, which is a drug marketed by Organon Sub Merck and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the BRIDION profile page.

The generic ingredient in BRIDION is sugammadex sodium. One supplier is listed for this compound. Additional details are available on the sugammadex sodium profile page.
Summary for 022225
Tradename:BRIDION
Applicant:Organon Sub Merck
Ingredient:sugammadex sodium
Patents:3
Pharmacology for NDA: 022225
Ingredient-typegamma-Cyclodextrins
Suppliers and Packaging for NDA: 022225
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225 NDA Merck Sharp & Dohme Corp. 0006-5423 0006-5423-12 10 VIAL, SINGLE-DOSE in 1 CARTON (0006-5423-12) > 2 mL in 1 VIAL, SINGLE-DOSE (0006-5423-02)
BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225 NDA Merck Sharp & Dohme Corp. 0006-5423 0006-5423-15 10 VIAL, SINGLE-DOSE in 1 CARTON (0006-5423-15) > 5 mL in 1 VIAL, SINGLE-DOSE (0006-5423-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrengthEQ 500MG BASE/5ML (EQ 100MG BASE/ML)
Approval Date:Dec 15, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 15, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ SubscribePatent Expiration:Jan 27, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:REVERSAL OF NEUROMUSCLUAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE
Patent:➤ SubscribePatent Expiration:Aug 7, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:REVERSAL OF NEUROMUSCLUAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Teva
McKesson
Healthtrust
Covington
Deloitte
Queensland Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot